Platinum‐based therapies are among the most commonly used cytotoxic anticancer drugs used at different stages of the treatment of EGFR‐mutant NSCLC [5, 22, 24, 25, 26, 27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.